Is Routine Therapeutic Drug Monitoring of Anti-Retroviral Agents Warranted in Children Living with HIV?

OBJECTIVE The utility of routine therapeutic drug monitoring (TDM) in children living with HIV has not been extensively studied. The purpose of this study was to assess this strategy. METHODS This was a single-center, prospective observational study of routine TDM for protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs) in children living with HIV who were receiving antiretroviral therapy (ART) between February and December 2014. Outcome measures included the proportion of serum antiretroviral (ARV) medication concentrations in the therapeutic range (target values extrapolated from adult data) and the effect of serum concentrations on virologic control, medication adherence, and toxicity. RESULTS Forty-eight children with a median age of 13 years (interquartile range, 3-18) were included. Median viral load (VL) and CD4% were <40 copies/mL (range, <40-124) and 37.4% (range, 8.4-47.9), respectively. Adherence was considered excellent in 95.8% of patients. Of the 50 serum trough concentrations (PI n = 19 [38%]; NNRTI n = 27 [54%]; INSTI n = 4 [8%]), 66% (n = 33) were in the therapeutic range, 12% (n = 6) were subtherapeutic, and 22% (n = 11) were supratherapeutic. There was no statistically significant correlation between serum ARV concentrations and patient demographics, VL, CD4%, or adherence. No clinically significant adverse events were noted. One dose adjustment was made for a subtherapeutic serum raltegravir concentration, likely attributable to interaction with ritonavir. CONCLUSIONS This study does not support routine TDM in healthy children living with HIV who are well controlled on antiretroviral medication regimens. A more targeted strategy, such as when adherence is questioned or when there are suspected drug interactions, may be more appropriate.

[1]  L. Wiesner,et al.  Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital. , 2019, Journal of tropical pediatrics.

[2]  K. Ruxrungtham,et al.  Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients , 2016, Expert review of clinical pharmacology.

[3]  M. Cotton,et al.  Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice? , 2014, Paediatrics and international child health.

[4]  G. Maartens,et al.  Plasma Lopinavir Concentrations Predict Virological Failure in a Cohort of South African Children Initiating a Protease-Inhibitor-Based Regimen , 2014, Antiviral therapy.

[5]  C. Fletcher,et al.  Pharmacometric Characterization of Efavirenz Developmental Pharmacokinetics and Pharmacogenetics in HIV-Infected Children , 2013, Antimicrobial Agents and Chemotherapy.

[6]  S. Urien,et al.  Evaluation of nevirapine dosing recommendations in HIV-infected children. , 2013, British journal of clinical pharmacology.

[7]  A. Walker,et al.  Pediatric Underdosing of Efavirenz: A Pharmacokinetic Study in Uganda , 2011, Journal of acquired immune deficiency syndromes.

[8]  H. Klinker,et al.  The Role of Therapeutic Drug Monitoring in the Management of Patients With Human Immunodeficiency Virus Infection , 2011, Therapeutic drug monitoring.

[9]  N. Rakhmanina,et al.  Pharmacokinetic Optimization of Antiretroviral Therapy in Children and Adolescents , 2011, Clinical pharmacokinetics.

[10]  E. Snoeck,et al.  Pharmacokinetics and Pharmacodynamics of the Non‐Nucleoside Reverse‐Transcriptase Inhibitor Etravirine in Treatment‐Experienced HIV‐1‐Infected Patients , 2010, Clinical pharmacology and therapeutics.

[11]  D. Burger.  The Role of Therapeutic Drug Monitoring in Pediatric HIV/AIDS , 2010, Therapeutic drug monitoring.

[12]  M. Neely,et al.  Can Therapeutic Drug Monitoring Improve Pharmacotherapy of HIV Infection in Adolescents? , 2010, Therapeutic drug monitoring.

[13]  N. Sheehan,et al.  Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice. , 2009, The Canadian journal of hospital pharmacy.

[14]  S. Urien,et al.  Is the Recommended Dose of Efavirenz Optimal in Young West African Human Immunodeficiency Virus-Infected Children? , 2009, Antimicrobial Agents and Chemotherapy.

[15]  J. van der Walt,et al.  Therapeutic drug monitoring of antiretrovirals for people with HIV. , 2009, The Cochrane database of systematic reviews.

[16]  M. Neely,et al.  Population Pharmacokinetics of Lopinavir Predict Suboptimal Therapeutic Concentrations in Treatment-Experienced Human Immunodeficiency Virus-Infected Children , 2009, Antimicrobial Agents and Chemotherapy.

[17]  M. Hughes,et al.  Early Initiation of Lopinavir/Ritonavir in Infants Less Than 6 Weeks of Age: Pharmacokinetics and 24-Week Safety and Efficacy , 2009, The Pediatric infectious disease journal.

[18]  A. Mangano,et al.  Pharmacokinetic Study of the Variability of Indinavir Drug Levels when Boosted with Ritonavir in HIV-Infected Children , 2008, Pharmacology.

[19]  W. Borkowsky,et al.  Pharmacokinetics of High-Dose Lopinavir-Ritonavir with and without Saquinavir or Nonnucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus-Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors , 2008, Antimicrobial Agents and Chemotherapy.

[20]  D. Burger,et al.  Use of therapeutic drug monitoring in HIV disease , 2008, Current opinion in HIV and AIDS.

[21]  L. Mofenson,et al.  Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in HIV‐infected Children Participating in an Area‐under‐the‐curve Controlled Trial , 2008, Clinical pharmacology and therapeutics.

[22]  C. Kovacs,et al.  Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.

[23]  R. Gross,et al.  A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. , 2004, Journal of clinical epidemiology.

[24]  J. Beijnen,et al.  Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs , 2004, Clinical pharmacokinetics.

[25]  R. de Groot,et al.  Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children , 2002, The Pediatric infectious disease journal.

[26]  R. de Groot,et al.  Efficacy of highly active antiretroviral therapy in HIV-1 infected children. , 2002, The Lancet. Infectious diseases.

[27]  A. Wu,et al.  Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments , 2000, AIDS care.